SGLT-2 inhibition and glucagon: Cause for alarm?

被引：29
|
作者：
Kibbey, Richard G. [1 ,2 ]
机构：
[1] Yale Univ, Sch Med, Dept Internal Med Endocrinol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA
来源：
TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2015年 / 26卷 / 07期
关键词：
SGLT-2; inhibitors; glucagon; alpha-cell; glucose production; HNF4alpha; PANCREATIC ALPHA-CELLS; GLUCOSE; DAPAGLIFLOZIN;
D O I：
10.1016/j.tem.2015.05.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Recent studies raised the alarm that the inhibition of sodium-coupled glucose transporter type-2 in humans increases endogenous glucose production rates by an unclear mechanism. Surprisingly, a potential explanation may be linked directly to the alpha-cell. Is this a mechanistic spoiler or an added benefit?
引用
收藏
页码：337 / 338
页数：2
相关论文
共 50 条
  • [1] SGLT-2 inhibition in patients with kidney disease
    Gilbert, R. E.
    [J]. DIABETES & METABOLISM, 2014, 40 : S23 - S27
  • [2] "Dip" in eGFR: Stay the Course With SGLT-2 Inhibition
    Umanath, Kausik
    Testani, Jeffrey M.
    Lewis, Julia B.
    [J]. CIRCULATION, 2022, 146 (06) : 463 - 465
  • [3] PROLONGED KETOACIDOSIS ASSOCIATED WITH SGLT-2 INHIBITION: A CASE REPORT
    Kohli, Jatinder
    Goldfarb, Stanley
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 69 (04) : A59 - A59
  • [4] Combined SGLT-2 and ACE Inhibition in chronic Kidney Disease
    Kahl, S.
    [J]. DIABETOLOGE, 2022, 18 (02): : 203 - 204
  • [5] Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus
    Miller, Kevin
    Miller, Eden M.
    [J]. JOURNAL OF FAMILY PRACTICE, 2015, 64 (12): : S54 - S58
  • [6] SGLT-2 inhibition in IgA nephropathy: the new standard of care?
    Barratt, Jonathan
    Floege, Juergen
    [J]. KIDNEY INTERNATIONAL, 2021, 100 (01) : 24 - 26
  • [7] Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
    Alsalim, Wathik
    Persson, Margaretha
    Ahren, Bo
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1652 - 1658
  • [8] SGLT2 inhibition and glucagon secretion in humans
    Saponaro, C.
    Pattou, F.
    Bonner, C.
    [J]. DIABETES & METABOLISM, 2018, 44 (05) : 383 - 385
  • [9] Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
    Bode, David
    Semmler, Lukas
    Wakula, Paulina
    Hegemann, Niklas
    Primessnig, Uwe
    Beindorff, Nicola
    Powell, David
    Dahmen, Raphael
    Ruetten, Hartmut
    Oeing, Christian
    Alogna, Alessio
    Messroghli, Daniel
    Pieske, Burkert M.
    Heinzel, Frank R.
    Hohendanner, Felix
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [10] Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
    David Bode
    Lukas Semmler
    Paulina Wakula
    Niklas Hegemann
    Uwe Primessnig
    Nicola Beindorff
    David Powell
    Raphael Dahmen
    Hartmut Ruetten
    Christian Oeing
    Alessio Alogna
    Daniel Messroghli
    Burkert M. Pieske
    Frank R. Heinzel
    Felix Hohendanner
    [J]. Cardiovascular Diabetology, 20
12345